![]() |
Sanofi Pasteur Korea General Manager Baptiste de Clarens, left, and Handok Chairman Kim Young-jin shake hands after signing an agreement on jointly promoting six vaccines in South Korea at the Seoul headquarters of Sanofi, Tuesday. Courtesy of Sanofi Pasteur |
By Park Ji-won
Sanofi Pasteur, the vaccine affiliate of healthcare company Sanofi, signed a promotion agreement for six vaccines with Korean pharmaceutical company Handok.
The six are Avaxim 160U for hepatitis A; Adacel a combined vaccine for adults to prevent diphtheria, tetanus and acellular pertussis; Menactra, a meningococcal A, C, Y, W-135 polysaccharide DT conjugate vaccine; Imojev for Japanese encephalitis, which is a live attenuated recombinant vaccine; Pentaxim, a conjugate combined vaccine for diphtheria, tetanus, acellular pertussis, inactivated poliovirus and haemophilus influenza type B; and Tetraxim, a combined vaccine fof adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated poliomyelitis.
Following the move, Handok for its part will promote eight vaccines from Sanofi Pasteur here, including Vaxigrip, a trivalent split-virion influenza vaccine, and VaxigripTetra a quadrivalent split-virion influenza vaccine.
"We are very excited about this milestone and look forward to further synergy gains based on the core capabilities of the two companies. We are committed to improving public health as a reliable partner in Korea in cooperation with Handok that has a lot of experience and a strong sales capability in the vaccine market," said Sanofi Pasteur General Manager Baptiste de Clarens.
In a statement Handok Chairman Kim Young-jin said, "We are pleased to provide a broader range of vaccines through our strengthened partnership with Sanofi Pasteur, amid renewed attention to vaccination due to an increase in hepatitis A cases. We will continue efforts to ensure the safe and stable delivery of quality vaccines in Korea to help improve the health of the people."